NASDAQ
6.91USD
+1.23 (+21.65%)
We have scored 9 news catalysts on Profound Medical Corp. (PROF) over the past 12 months. The biggest single-day move next to one of them came Oct 9, 2026, when PROF closed +21.7%: “Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?”. Coverage across the window leans positive (average ticker sentiment +0.58). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
251.1M
P/E
—
EPS
—
Beta
0.53
52W range
4.8-8.95
Day range
6.15–6.92
Open
6.15
Prev close
5.68
Volume
3M
Avg volume
108.2K
Dividend
0.00
IPO
2019-10-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Profound Medical Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PROF: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
